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Цел на трудот беше да се евалуираат клиничките карактеристики на COVID -19 и успехот на терапијата 
кај децата. Материјал и методи: Во студијата беа вклучени 218 педијатриски пациенти суспектни за 
COVID-19 инфекција, хоспитализирани во Институтот по белодробни заболувања кај децата-Козле, 
во период од 16-ти март до 19-ти јуни 2020 година. Сите пациенти беа тестирани за SARS-CoV-2 ви-
рус во назофарингеален брис со real-time reverse transcription polymerase chain reaction (RT-PCR)  во 
Институтот за јавно здравје на Република Северна Македонија. Клинички симптоми, рендгенграфии 
и лабораториски параметри беа вклучени во студијата. Резултати: Од вкупно 218 хоспитализирани 
пациенти, само 9 (4,13% ) беа со позитивен резултат за COVID -19. Од испитаните пациенти 59% беа 
машки. Доенчиња под една година со потешка клиничка слика беа 44,4%. Сите позитивни пациенти 
беа со средно тешки симптоми. 66,6% од хоспитализираните деца беа со покачена температура и пул-
монални симптоми и 22,2% манифестираа гастроинтестинални симптоми. Макролидите беа лек на из-
бор кај 88%, а 77% примаа интравенска терапија и 33% инхалирачки бронходилататор. Заклучок: Мал 
број деца беа инфицирани со COVID -19. Сите позитивни пациенти беа со средно тешки симптоми, и 
дадоа добар одговор на спроведениот третман. Сепак, влијанието на овој вирус врз понатамошното 
здравје на децата како и улогата на децата во пренесување на вирусот останува недоволно познато. 
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The aim of the paper was to evaluate clinical characteristics of COVID-19 in children and the 
success of the treatment. Material and methods: The study included 218 pediatric patients 
suspected for COVID-19 hospitalized at the Institute for Pulmonary Diseases in Children-Skopje, 
during the period from 16th of March to 19th of June 2020. All patients were tested for presence 
of SARS-CoV-2 virus in nasopharyngeal swab with real-time reverse transcription polymerase 
chain reaction (RT-PCR) in the Institute of Public Health of Republic of North Macedonia. 
Clinical symptoms, X-ray and laboratory findings were included in the study. Results: From 218 
hospitalized patients, only 9 (4.13%) were positive for COVID-19 and 59% of them were males. 
Infants, with moderate pulmonary disease were 44.4% of the patients. Fever and gastrointestinal 
symptoms were present in 66.6% and 22.2% of the children, respectively. Macrolides were therapy 
of choice in 88% of the treated patients, 77% received intravenous therapy, 33% were on inhaled 
bronchodilator. Conclusions: A small number of children had COVID-19. All infected children were 
with mild to moderate pulmonary symptoms and reacted satisfactory to the treatment. However, 
the importance of transmitting the virus and influence over children’s health remains uncertain.
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Introduction
Coronaviruses are a large family 
of viruses which may cause illness 
in animals or humans. In humans, 
several coronaviruses are known to 
cause respiratory infections rang-
ing from the common cold to more 
severe diseases such as Middle East 
Respiratory Syndrome (MERS) and 
Severe Acute Respiratory Syndrome 
(SARS) caused by SARS-CoV-1 virus1. 
The most recently discovered severe 
acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) causes so called 
COVID-19, an infectious disease that 
causes enormous morbidity and mor-
tality in the whole world. This new 
virus and disease were unknown be-
fore the outbreak in Wuhan, China, 
in December 20192. COVID-19 is now 
a pandemic affecting mostly elderly, 
but also children in many countries 
globally. 
Compared to adults SARS-CoV-1, 
MERS-CoV and SARS-CoV-2 seem to 
affect children less commonly and 
cause fewer symptoms. Preliminary 
evidence suggests children are just 
as likely to become infected with 
SARS-CoV-2 as adults, but are less 
likely to be symptomatic or to devel-
op severe symptoms3,4. However, the 
importance of children in transmit-
ting the virus and the importance 
of influence of this virus on child’s 
future health and wellbeing is still 
uncertain (7,8).
The aim of this paper was to evaluate 
clinical characteristics of COVID-19 
and success of the treatment in chil-
dren.
Material and methods 
The study included 218 pediatric pa-
tients suspected for COVID-19, hos-
pitalized at the Institute for Pulmo-
nary Diseases in Children-Skopje, 
during the period from 16th of March 
to 19th of June. All patients were test-
ed for presence of SARS-CoV-2 virus 
in the nasopharyngeal swabs using 
LightMix SarbecoV E-gene plus EAV 
control, TIB MOLBIOL and LightMix 
Modular Wuhan CoV RdRP-gene, 
TIB MOLBIOL9. These tests pres-
ent real-time reverse transcription 
polymerase chain reaction (RT-PCR) 
technology and were performed at 
the Institute of Public Health of Re-
public of North Macedonia in Skopje. 
We analyzed clinical symptoms, lung 
X-rays and laboratory findings in this 
study.
Results
From a total of 218 patients tested 
for SARS-CoV-2, 41% were females, 
and 59% males. According to age, all 
of them were from 5 days old to 15 
years, but most of them belonged to 
the group under one year old (27.5%), 
from 1 year - 2 years were 22% and 
14.6% from 2 years - 3 years. Most of 
them originated from Skopje (84.4%).
All COVID-19 patients had mild to 
moderate symptoms, 66.6% had high 
fever and pulmonary symptoms: in-
creased cough, dyspnea, chest tight-
ness, wheezing, sputum production, 
hemoptysis. 22% had gastrointesti-
nal symptoms: diarrhoea, vomiting/
nausea, abdominal pain. Most of the 
COVID-19 patients (44.4%) were one 
year old or younger. 
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Clinical characteristics of COVID-19 
in our patients were:
• Pulmonary symptoms: increased 
cough, dyspnea, chest tightness, 
wheezing, sputum production, 
hemoptysis
• Fever/General symptoms: fever, 
fatigue, headache, arthralgia/my-
algia
• Gastrointestinal symptoms: diar-
rhea, vomiting/nausea, abdomi-
nal pain
• Other symptoms: none of the 
above
• But, most of the COVID-19 pa-
tients had high fever and pul-
monary symptoms, and some of 
them had gastrointestinal and 
other symptoms (Graph 2).
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Graph 1.  Age distribution of patients with COVID-19  
Graph 2.  Presentation of clinical characteristics in patients with COVID-19  
Graph 3.  Individual symptoms in patients with COVID-19  
Individual symptoms in patients are presented in graph 3.
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Table 1.  Blood test results in positive patients with COVID-19
Vol. 12 No.3 2020
Laboratory analysis in patients with 
COVID-19 
Lymphopenia, neutrophilia, high 
CRP, and high procalcitonin levels 
may be associated with greater illness 
severity. We did not find elevated 
serum alanine aminotransferase and 
aspartate aminotransferase levels, 
elevated lactate dehydrogenase levels 
in our patients (table 1).
Urine culture - In only one Covid-19 
patient, Escherichia coli ESBL+ was 
isolated. 
Blood culture – All blood cultures 
remained sterile after incubation.
Chest X-rays of children with 
COVID-19 are presented in Picture 1 
to Picture 3. 
Graph 4.  CRP value in patients with COVID-19
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Picture 1.  Chest x-ray of a 6-month-old child with COVID-19, with bilateral emphysema  
 and bronchiectasis in the right lower lobe.
Picture 2.  Chest x-ray of a one-year old child with COVID=19, with bilateral emphysema  
 and bronchiectasis in the middle lobe.
10
Vol. 12 No.3 2020
Picture 3.  Chest x-ray of a 4-month-old child with COVID -19, with bilateral air-space  
 consolidation.
Table 2.  COVID-19 drug treatment
All COVID -19 patients were treated 
with azithromycin, but because of 
moderate pulmonary disease many 
of them received intravenous third 
generation cephalosporins (77.7%), 
34% inhaled bronchodilator and had 
symptomatic therapy (Table 2).
All COVID-19 patients reacted 
satisfactory to the treatment and they 
left the hospital in a stable condition.
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Discussion
Children of all ages can become ill 
with coronavirus disease (COVID-19). 
But most of them who are infected 
do not become as sick as adults 
and some might not show any 
symptoms at all 1,2,3. Children also 
rarely experience severe illness with 
COVID-19. Children under the age of 
1 (infants) are at higher risk of severe 
illness with COVID-19 4,5. This is 
likely due to their immature immune 
systems and smaller airways, which 
make them develop breathing issues 
with respiratory virus infections 6,7. 
A study of more 2100 children with 
suspected or confirmed COVID-19 
in China showed that 11% of infants 
had a severe or critical illness, about 
7% of children ages 1 to 5, 4% of those 
6 to 10 years and 4% of those 11 to 15 
years 4,5,8.
During the stay in our hospital 
all patients had mild to moderate 
pulmonary and gastrointestinal 
symptoms. None of the treated 
patients needed oxygen therapy. All 
positive patients reacted well to the 
treatment and were discharged from 
hospital in a good condition.
Conclusion
This is the first published study of 
COVID-19 in children in the Republic 
of North Macedonia in which we 
found a small number of children 
with COVID-19. They had mild to 
moderate pulmonary symptoms 
and reacted well to the treatment. 
However, the importance of 
influence of this virus on child’s 
future health and wellbeing is still 
uncertain, also transmission of the 
virus from asymptomatic children 
to other people is unknown.  
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